{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:59Z","timestamp":1792605779406,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:34:46Z","timestamp":1704461686000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy"],"prefix":"10.1016","volume":"123","author":[{"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.01.001_bib0001","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0002","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0004","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-022-10247-5","article-title":"Endomyocardial biopsy in the clinical context: current indications and challenging scenarios","volume":"28","author":"Porcari","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.01.001_bib0006","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.001_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.001_bib0009","first-page":"424","article-title":"[Ten questions for the cardiologist about cardiac scintigraphy with bone tracers, amyloidosis and the heart]","volume":"23","author":"Porcari","year":"2022","journal-title":"G Ital Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0010","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2024.01.001_bib0011","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/eurjpc\/zwac237","article-title":"Comparison of different technetium-99m-labelled bone tracers for imaging cardiac amyloidosis","volume":"30","author":"Porcari","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2024.01.001_bib0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0013","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-imaging characterization of cardiac phenotype in different types of amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"16","key":"10.1016\/j.ejim.2024.01.001_bib0017","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"issue":"45","key":"10.1016\/j.ejim.2024.01.001_bib0018","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"issue":"31","key":"10.1016\/j.ejim.2024.01.001_bib0019","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0022","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0023","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0024","first-page":"211","article-title":"Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis","volume":"29","author":"Cappelli","year":"2022","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.001_bib0025","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.001_bib0026","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Hear Rhythm"},{"key":"10.1016\/j.ejim.2024.01.001_bib0027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0028","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. a systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0029","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ehf2.13606","article-title":"Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery","volume":"9","author":"Porcari","year":"2022","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0030","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0031","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhsa.2022.02.013","article-title":"Prevalence and subtypes of tenosynovial amyloid in patients undergoing carpal tunnel release","volume":"47","author":"DiBenedetto","year":"2022","journal-title":"J Hand Surg Am"},{"key":"10.1016\/j.ejim.2024.01.001_bib0032","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0033","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy \u2013 from diagnosis to prognosis","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0034","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.2824","article-title":"Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis","volume":"25","author":"Aimo","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.ejim.2024.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0036","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0037","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of national amyloidosis centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0038","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0039","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0040","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0041","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0042","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","article-title":"Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly indian population: a pilot study","volume":"3","author":"Singal","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0043","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0044","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2024.01.001_bib0046","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","article-title":"Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes","volume":"25","author":"Vranian","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0047","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0048","article-title":"Prevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis","volume":"23","author":"Porcari","year":"2021","journal-title":"Eur Hear J Suppl"},{"key":"10.1016\/j.ejim.2024.01.001_bib0049","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0050","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"Amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.01.001_bib0051","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2024.01.001_bib0052","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejim.2024.01.001_bib0053","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.001_bib0054","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.01.001_bib0055","unstructured":"Presented by Julian D Gillmore at the European Society of Cardiology Congress, Amsterdam, Netherlands, August 27, 2023 https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/08\/24\/02\/29\/attribute-cm."},{"key":"10.1016\/j.ejim.2024.01.001_bib0056","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.001_bib0057","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.001_bib0058","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.001_bib0059","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis\u2013related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.001_bib0060","unstructured":"Presented by David Adams at the Soci\u00e9te\u00e9 Francophone du Nerf P\u00e9riph\u00e9rique Annual Meeting, Paris, January 21, 2022 https:\/\/alnylampharmaceuticalsinc.gcs-web.com\/static-files\/f3ea68f2-a4d8-4753-8fc4-6c3b7ccf6218."},{"key":"10.1016\/j.ejim.2024.01.001_bib0061","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.001_bib0062","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T18:59:53Z","timestamp":1715108393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":62,"alternative-id":["S0953620524000013"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}